Apoorva Mohan

发表

kinase isoform reduces neuropathic and postoperative pain and TLR 4-induced pain in male mice

B. Fitzsimmons, N. Terrando, R. Ji, 2017 .

Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice

B. Fitzsimmons, R. Ji, Lin-lin Zhang, 2017, Brain, Behavior, and Immunity.

Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain

B. Fitzsimmons, H. Kordasiewicz, E. Swayze, 2018, Pain.

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models

J. Svaren, S. Scherer, M. Scheideler, 2017, The Journal of clinical investigation.

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

K. Luk, A. Cole-Strauss, C. Bennett, 2021, JCI insight.

Loss of MBNL leads to disruption of developmentally regulated alternative polyadenylation in RNA-mediated disease.

Chaolin Zhang, M. Swanson, K. Sobczak, 2014, Molecular cell.

Compound loss of muscleblind-like function in myotonic dystrophy

M. Swanson, L. Ranum, Christopher M. Chamberlain, 2013, EMBO molecular medicine.

RNA–protein interactions in unstable microsatellite diseases

M. Swanson, M. Goodwin, Apoorva Mohan, 2014, Brain Research.

MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.

Sebastien M. Weyn-Vanhentenryck, L. Buée, Chaolin Zhang, 2015, Cell reports.

MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response

M. Swanson, N. Salomonis, J. Molkentin, 2015, Nature Communications.

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

K. Luk, A. Cole-Strauss, C. Bennett, 2019, bioRxiv.